CClinicalTrials.gg
RecruitingNCT05879770Wire vs ProlenUpdated May 30, 2023

Is the Use of Prolene as Sufficient as the Use of Wire in Shouldice Surgery to Keep the Recurrence Rate Low After One Year?

An observational study in Inguinal Hernia, sponsored by Shouldice Hospital. Recruiting at 1 site in Canada. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-30.

Sponsored by Shouldice Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,400
Ages
16 Years and older
Sex
All
01

Study summary

When conducting the Shouldice procedure the 4-layer suture of the transversalis fascia is usually done with Prolene worldwide. At the Shouldice hospital the wire has originally been used for these augmentation. During the last decade several Shouldice Surgeons started to use the Prolene due to occasional delivery problems of the wire from Germany.

The 1-year- recurrence rate at the Shouldice hospital is 1,15% (mainly wire-use). The published 1-year recurrence rate in Europe is 2%.

As quality assessment, this project intends to evaluate these two options for suturing (wire vs Prolene) in the elective inguinal hernia patient in terms of 1-year recurrence rate. The population of focus will be those who had a primary or secondary inguinal hernia operation at Shouldice Hospital and the project is estimated to take 3 months.

Read the detailed description

a. Study design A total of 1400 patients (n=700 with wire; n=700 with Prolene) who underwent Shouldice surgery at Shouldice Hospital will be contacted by telephone. They will be asked whether a relapse occurred after their surgery.

Sample size calculation:

The 1-year recurrence rate at Shouldice Hospital is 1.15% (mainly wire use). The published 1-year recurrence rate in Europe is 2% [1-3]. Statistics: non-inferiority: delta for non-inferiority (defined equivalence range) = 1%. Total N = 1120 (0% dropout), with 20% dropout: N = 1400.) The same number of patients will be analyzed with regard to Shouldice repair due to a first relapse (time period of data extraction 2019-2021).

Since over 6000 hernias are operated annually, a consecutive data extraction of patients operated in 2021 will be performed.

02

Conditions studied

  • Inguinal Hernia

Keywords

  • Hernia, Shouldice Repair, groin hernia
03

In context

Recurrence

4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.

This study's planned enrollment of 1,400 is above the median of 200 across 702 observational studies indexed under Recurrence.

Browse Recurrence studies →

Lead sponsor

Shouldice Hospital is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult patients of all sexes who have undergone inguinal hernia surgery in Shouldice technique.

Inclusion criteria

  • Adult patients of all sexes who have undergone inguinal hernia surgery in Shouldice technique.

Exclusion criteria

Exclusion Criteria:

  • Hernia repair using a mesh
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,400 participants (estimated)
Patient registry
No

Groups and cohorts

  • Wire group

    Patients who underwent Shouldice inguinal hernia repair using wire.

    Other: suture material

  • prolene group

    Patients who underwent Shouldice inguinal hernia repair using prolene.

    Other: suture material

Interventions

  • Othersuture material

    Some patients have had a shouldice repair with wire in the past and others with Prolene.

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    One-year recurrence rate

    Time frame: 1 year

Secondary outcomes

  1. Reoperation rate due to a recurrence

    Reoperation rate due to a recurrence

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Shouldice Hospital
    Thornhill, Ontario L3T 4A3,, Canada
    • Marguerite Mainprize, MSc · Contact · mmainprize@shouldice.com · 905-889-1125 ext. 1297
    • Fernando Netto Spencer, PhD · Contact · fspencernetto@shouldice.com · 905-889-1125 ext. 1297
    • Christoph Paasch, PD Dr. · Sub investigator
    • Marguerite Mainprize, MSc · Sub investigator
    • Fernando Netto Spencer, PhD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05879770
Lead sponsor
Shouldice Hospital
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Sep 1, 2023 (estimated)
Primary completion
Jan 1, 2024 (estimated)
Completion
Mar 1, 2024 (estimated)
Last update
May 30, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion